Interview with Optceutics speaker released for Ophthalmic Drugs Conference

300x300 copy
300x300 copy
Spread the Word
Listed Under



Bermondsey - London, Greater - England


BERMONDSEY, England - Oct. 14, 2019 - PRLog -- SMi Group Reports: CSO of Optceutics Ltd to present at SMi's Ophthalmic Drugs conference commencing on 18th- 20th November 2019, in London

The Ophthalmic Drugs conference will take place on the 18th- 20th November 2019 in London. The event aims to explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort, and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.

With only 6 weeks until the conference, SMi caught up with the CSO of Optceutics Ltd, Sahar Awwad as a speaker for Europe's leading Ophthalmic Drugs conference.

Dr. Awwad will present on 'The need of an in vitro ocular model for preclinical testing of intraocular formulations' focussing on:

·         The need for longer acting formulations

·         Challenges during preclinical development-use of animal models, lack of models in the pharmacopeia and biopharmaceutical formulation challenges

·         Development and capabilities of the PK-Eye with a few case studies

Excerpt of Sahar's interview:

The ophthalmic drugs market has matured greatly over recent years, what are the key significant developments you have noticed over the past year?

"My work focuses on developing long acting methodologies to deliver drugs to the back of the eye. In terms of retinal diseases, antibody-based medicines have transformed the treatment of blinding disease such as AMD in the last 2 decades. Prolonging the duration of action is a critical, the unmet healthcare challenge is to reduce the frequency of injections. There are no clinically licensed implantable, long acting formulations for therapeutic proteins or anti-VEGFs…"

What do you personally see as the greatest challenge to overcome in the field of Ophthalmic Drugs at the moment?

"One of the greatest challenges to overcome is the development of long acting medicines to reduce the frequency of injections into the eye. During preclinical testing, industries heavily rely on animal models for optimisation and screening..."

For the full speaker interview, speaker line-up, as well as the latest brochure and past attendees, go to the download at (

Ophthalmic Drugs Conference

18th – 20th November 2019

Copthorne Tara Hotel, London, UK

Proudly sponsored by:


Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168.

Media enquiries contact Neill Howard +44 (0) 207 827 6164.

Neill Howard
Email:*** Email Verified
Location:Bermondsey - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share